Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I.
Lasagna A, et al. Among authors: schiavo r.
ESMO Open. 2022 Apr;7(2):100458. doi: 10.1016/j.esmoop.2022.100458. Epub 2022 Mar 11.
ESMO Open. 2022.
PMID: 35427842
Free PMC article.